Document Detail

Naptumomab estafenatox: a new immunoconjugate.
MedLine Citation:
PMID:  20053143     Owner:  NLM     Status:  MEDLINE    
IMPORTANCE OF THE FIELD: New agents that specifically engage the immune system are being tested in a variety of malignancies. This review provides an overview of naptumomab, an immunotoxin, with encouraging clinical activity in Phase I trials. AREAS COVERED IN THIS REVIEW: This review examines the preclinical and the published clinical data with regards to naptumomab. WHAT THE READER WILL GAIN: This review provides the reader with an understanding of the mechanism of action, immunology, pharmacokinetics and clinical activity of this agent. TAKE HOME MESSAGE: Naptumomab has a unique mechanism of action and appears to be an active agent in the treatment of refractory solid tumors such as renal cell carcinoma.
Matthew K Robinson; R Katherine Alpaugh; Hossein Borghaei
Related Documents :
6854663 - Cerebral aneurysm: report of two cases and clinical update.
3701343 - Clinical signs in the wernicke-korsakoff complex: a retrospective analysis of 131 cases...
17964363 - Acute aortic dissection.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on biological therapy     Volume:  10     ISSN:  1744-7682     ISO Abbreviation:  Expert Opin Biol Ther     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-01-21     Completed Date:  2010-04-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101125414     Medline TA:  Expert Opin Biol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  273-9     Citation Subset:  IM    
Fox Chase Cancer Center, Department of Medical Oncology, 333 Cottman Ave, Philadelphia, PA 19111, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / adverse effects,  chemistry,  pharmacokinetics,  pharmacology,  therapeutic use*
Antineoplastic Agents / adverse effects,  chemistry,  pharmacokinetics,  pharmacology,  therapeutic use*
Clinical Trials, Phase I as Topic
Drug Design
Enterotoxins / adverse effects,  chemistry,  pharmacokinetics,  pharmacology,  therapeutic use*
Immunoconjugates / adverse effects,  chemistry,  pharmacokinetics,  pharmacology,  therapeutic use*
Neoplasms / drug therapy*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/Enterotoxins; 0/Immunoconjugates; 676258-98-3/naptumomab estafenatox

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency viru...
Next Document:  Combination therapy with angiotensin-converting enzyme inhibitors and indapamide impairs glucose tol...